Stem Cell Research Opens the Door for Novel Biodrug Development
A New Report From Biocompare, Inc. Finds That Invitrogen and BD Biosciences Share the Bulk of Stem Cell Market Share in a Competitive Environment
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- February 13, 2006 -- A new report from Biocompare, Inc., Stem Cell Culture: Opportunities in an Emerging Market, based on a survey of over 200 researchers, finds that scientists are using stem cells to generate data that are aimed at directing new drug development programs in gene therapy, tissue engineering, and in many disease and autoimmune disorders. Immunohistochemistry, RT-PCR, and flow cytometry are the stem cell differentiation tests of choice and find the top vendors strongly competing with one another in a very tight market.
The survey explores the different species and cell types being used and examines which suppliers of stem cell-related products researchers are using. Invitrogen and BD Biosciences top the list of the most popular companies, but there is fierce competition growing amid mergers and acquisitions of niche cell culture companies. The report discusses the technologies used and areas that require the most improvement. Of note is that the area of stem cell isolation and characterization tools is a target on which vendors should focus to improve. Such progress will advance the wealth of applications available to current and future stem cell researchers.
Purchases of tissue culture consumables fuel the growth of revenue in the stem cell market, as the use of growth supplements and antibodies are high on the wish lists of researchers in this area. Important vendor characteristics of quality, reliability, and value were selected to be critical for making informed purchase decisions. Vendors should continue to hone their customer service attributes to successfully compete in this market.
The clinical applications of stem cells are predicted to bring financial benefit to companies in this research area. The overall cell culture market, including media, sera, and reagents, is already topping $1 billion and is expected to grow by a rate of over 12% annually. While the U.S. and Europe dominate the cell culture market, the U.S. revenue stream is closely linked to available funds in the stem cell area, in addition to the increasing set of biologic drugs that are growing at approximately 20% per year. Such progress also requires the growth of biomanufacturing, which will also depend heavily on cell culture products and cultured mammalian cell.
This report, Stem Cell Culture: Opportunities in an Emerging Market, available from Biocompare, Inc., explores researchers' purchasing plans and research approaches in the area of stem cell culture applications. More information about this and other reports available from Biocompare can be found at: http://www.biocompare.com/research
Biocompare, Inc. (http://www.biocompare.com), headquartered in South San Francisco, California, is a global media company informing and connecting the buyers, users, and sellers of life science products. By combining an in-depth knowledge of life science products and new technologies with the power of the internet, Biocompare offers a dynamic, relevant, and innovative media-based marketplace for life science information.